Advertisement

Long term administration of (—)-deprenyl increases mortality in male Wistar rats

  • I. M. Gallagher
  • A. Clow
  • V. Glover
Part of the Journal of Neural Transmission. Supplement book series (NEURAL SUPPL, volume 52)

Summary

Long term administration of the monoamine oxidase inhibitor (—)-deprenyl (0.5mg/Kg) for up to 20 months significantly increased mortality in the male Wistar rat, whereas the dopamine agonist pergolide (0.4mg/Kg) and the antioxidant diethyldithiocarbamate (400mg/Kg) had no significant effect on mortality. The increased mortality was not related to dietary intake or body weight of the rats. This is of interest in the light of recent evidence that (—)-deprenyl increases mortality in humans.

Keywords

Life Span Monoamine Oxidase Inhibitor Reduce Food Intake Term Administration Daily Food Intake 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Birkmayer W, Knoll J, Rieder P, Youdim MBH, Hars V, Marton J (1995) Increased life expectancy resulting from L-deprenyl addition to Madopar treatment in Parkinson’s disease: a long term study. J Neural Transm 64: 113–127CrossRefGoogle Scholar
  2. Carrillo M-C, Kitani K, Kanai S, Sato Y, Miyasaka K, Ivy GO (1994) The effect of a long term (6 months) treatment with (-)deprenyl on antioxidant enzyme activities in selective brain regions in old female Fischer 344 rats. Biochem Pharmacol 47(8): 1333–1338PubMedCrossRefGoogle Scholar
  3. Kitani K, Kanai S, Sato Y, Ohta, Ivy GO, Carrillo M-C (1992) Chronic treatment of (—)-deprenyl prolongs the life span of male Fischer 344 rats. Further evidence. Life Sci 52: 281–288CrossRefGoogle Scholar
  4. Knoll J (1988) The striatal dopamine dependency of life span in male rats. Longevity study with (-)deprenyl. Mech Ageing Dev 46: 237–262CrossRefGoogle Scholar
  5. Knoll J (1994) Angiohypotensin. In: Szekebres L, Papp JG (eds) Pharmacology of smooth muscle. Springer, Berlin Heidelberg New York Tokyo (Handbook Exp Pharmacol 111)CrossRefGoogle Scholar
  6. Lees AJ (1995) Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson’s disease. BMJ 311: 1602–1607PubMedCrossRefGoogle Scholar
  7. Milgram NW, Racine RJ, Nellis P, Mendonca A, Ivy GO (1990) Maintenance on L-deprenyl prolongs life in aged rats. Life Sci 47: 415–420PubMedCrossRefGoogle Scholar
  8. Weindruch R, Walford RL (1988) The retardation of aging and disease by dietary restriction. Charles C. Thomas, SpringfieldGoogle Scholar
  9. Yen TT, Knoll J (1992) Extension of life span in mice treated with Dinh lang (Policias fruticosum L) and (-)deprenyl. Acta Physiol Hungarica 79: 119–124Google Scholar

Copyright information

© Springer-Verlag Wien 1998

Authors and Affiliations

  • I. M. Gallagher
    • 1
    • 1
  • A. Clow
    • 2
  • V. Glover
    • 1
  1. 1.Department of PaediatricsQueen Charlotte’s sand Chelsea HospitalLondonUK
  2. 2.School of Biological & Health SciencesUniversity of WestminsterLondonUK

Personalised recommendations